Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) shares gapped up prior to trading on Monday after Citizens Jmp raised their price target on the stock from $32.00 to $39.00. The stock had previously closed at $26.24, but opened at $27.47. Citizens Jmp currently has a market outperform rating on the stock. Zymeworks shares last traded at $27.2150, with a volume of 88,663 shares traded.
A number of other research firms have also weighed in on ZYME. Stifel Nicolaus set a $46.00 price objective on Zymeworks in a research report on Friday, August 7th. HC Wainwright boosted their target price on Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Wells Fargo & Company increased their target price on Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Jefferies Financial Group restated a “buy” rating and set a $52.00 price target on shares of Zymeworks in a report on Friday, October 23rd. Finally, Citigroup lifted their price target on Zymeworks from $39.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, November 11th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $43.25.
View Our Latest Stock Report on ZYME
Insider Activity
In other Zymeworks news, EVP Adam Schayowitz sold 13,832 shares of the company’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $25.85, for a total transaction of $357,557.20. Following the transaction, the executive vice president owned 23,205 shares in the company, valued at approximately $599,849.25. This represents a 37.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul Moore sold 39,741 shares of the business’s stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $26.07, for a total transaction of $1,036,047.87. Following the transaction, the insider directly owned 33,756 shares of the company’s stock, valued at $880,018.92. The trade was a 54.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 37.73% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Zymeworks
A number of large investors have recently added to or reduced their stakes in the stock. Nykredit A S purchased a new stake in Zymeworks during the 2nd quarter valued at $25,000. Sterling Capital Management LLC grew its holdings in shares of Zymeworks by 813.3% in the third quarter. Sterling Capital Management LLC now owns 1,507 shares of the company’s stock worth $40,000 after acquiring an additional 1,342 shares during the period. State of Wyoming bought a new stake in shares of Zymeworks in the second quarter worth $73,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zymeworks in the third quarter worth $96,000. Finally, State of Alaska Department of Revenue purchased a new stake in Zymeworks during the third quarter valued at $102,000. Institutional investors own 92.89% of the company’s stock.
Zymeworks Price Performance
The business has a 50-day moving average of $27.32 and a 200 day moving average of $25.48. The company has a market cap of $1.86 billion, a PE ratio of 51.81 and a beta of 1.32.
Zymeworks (NASDAQ:ZYME – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.01. The business had revenue of $512.92 million for the quarter, compared to analysts’ expectations of $227.40 million. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The business’s revenue for the quarter was up 828.7% on a year-over-year basis. During the same period last year, the firm posted ($0.26) earnings per share. On average, equities analysts predict that Zymeworks Inc. will post 1.31 EPS for the current fiscal year.
Zymeworks Company Profile
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Read More
- Five stocks we like better than Zymeworks
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
